Skip to main content
SSO 2024 Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded for On-Demand Viewing
Recorded for On-Demand Viewing
Back

Skye C. Mayo, MD MPH (he/him/his)

Associate Professor
Department of Surgery, Division of Surgical Oncology, Oregon Health & Science University; Knight Cancer Institute; Portland, OR 97239 USA
Portland, Oregon, United States

Dr. Skye C. Mayo, MD, MPH, is an Associate Professor of Surgical Oncology at Oregon Health & Science University (OHSU) and the Knight Cancer Institute in Portland, Oregon. He is board certified in both Complex General Surgical Oncology and in General Surgery having completed a surgical residency at Johns Hopkins and a surgical oncology fellowship at Memorial Sloan Kettering. His clinical practice serves patients with cancers of the liver, bile ducts, gallbladder, and pancreas. He founded and serves as the Director of the Hepatic Arterial Infusion (HAI) Program at the OHSU Knight Cancer Institute. His research focuses on early phase clinical trial development for patients with cancers of the liver and bile ducts, including intrahepatic cholangiocarcinoma and metastatic colorectal cancer to the liver. He is the Principal Investigator on two investigator-initiated trials in HAI for patients with cholangiocarcinoma, serves as the site investigator for several consortium and cooperative group hepatobiliary oncology trials, and is the national SWOG Champion for the EA2222 PUMP trial (NCT 05863195). He is the Co-Chair of the Knight Cancer Institute Clinical Research Review Committee charged with providing peer review of the scientific merit of all cancer related research studies to be conducted at OHSU. He has an active basic science collaboration with scientists in the Knight Cancer Institute. Through this collaboration he mentors several residents a year in his research efforts toward the early detection of recurrent cancer and monitoring responses to treatment in patients with colorectal cancer metastatic to the liver, cholangiocarcinoma, and pancreatic cancer.

Presentation(s):